Skip Navigation


Annals of Oncology Advance Access originally published online on December 11, 2008
Annals of Oncology 2009 20(3):454-459; doi:10.1093/annonc/mdn663
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/3/454    most recent
mdn663v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Antón, A.
Right arrow Articles by Fernández, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Antón, A.
Right arrow Articles by Fernández, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

breast cancer

Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study

A. Antón1,*, A. Ruiz2, M. A. Seguí3, L. Calvo4, M. Muñoz5, J. Lao1, F. Sancho2 and L. Fernández3

1 Hospital Universitario Miguel Servet, Zaragoza
2 Instituto Valenciano de Oncología, Valencia
3 Consorci Sanitari Parc Taulí, Sabadell (Barcelona)
4 Complejo Hospitalario Juan Canalejo, A Coruña
5 Hospital Clínic i Provincial, Barcelona. Members of Spanish Breast Cancer Research Group (GEICAM), Spain

* Correspondence to: Dr A. Antón, P° Isabel La Católica 1, 50009 Zaragoza, Spain. Tel: +34-976765560; Fax: +34-976359268; E-mail: aantont{at}salud.aragon.es

Background: We carried out a phase I clinical trial to establish the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of the combination of liposome-encapsulated doxorubicin citrate (LD) and docetaxel in breast cancer patients.

Patients and methods: Patients with HER-2-overexpressing stages II and IIIA breast cancers were treated in different dose cohorts of three patients. The MTD cohort was expanded up to six patients. The patients received LD and docetaxel every 21 days, plus weekly trastuzumab, with pegfilgrastim support.

Results: A total of 20 patients were enrolled, 18 of them being assessable for toxicity and response. DLTs observed for this combination were diarrhea, fatigue, febrile neutropenia, stomatitis, myalgia, and nonneutropenic infection (pneumonia). LD 50 mg/m2 and docetaxel 60 mg/m2 every 21 days have been the MTD, with no episode of DLT observed. Seven patients developed left ventricular ejection fraction decline (six grade 1 and one grade 2). No interruptions of the treatment were needed as a consequence of cardiac toxicity. Pathologic complete response was achieved in eight patients (44%).

Conclusions: The MTD and recommended dose for phase II trials of LD and docetaxel are 50 and 60 mg/m2, respectively. The achieved results on cardiotoxicity are promising.

Key words: Her2 positive, breast cancer, neoadjuvant chemotherapy, liposomal doxorubicine, docetaxel, trastuzumab, cardiotoxicity

Received for publication August 26, 2008. Accepted for publication September 5, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.